Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 52Terminated 10Unknown 7Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Hodgkin Disease 6Sarcoma 3Melanoma 2Leiomyosarcoma 2Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Melanoma, Cutaneous Malignant 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hyperthermia 1Advanced Melanoma 1

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Dacarbazine × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06703398 2025-12-23

MIZAR-003

Shanghai Juncell Therapeutics

Phase 2 Recruiting
98 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡